化疗切换用于不响应或在胰腺腺癌新辅助化疗的进展
Brendan L Hagerty1, Fatemeh Fekrmandi2, Tyce Schneider3
1Department of Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
Journal of surgical oncology
|August 19, 2024
概括
对胰腺癌初始新辅助疗法没有反应的患者,切除选择有限. 然而,如果可能的话,应该继续进行外科探索和切除,并考虑对不响应者进行化疗切换.
科学领域:
- 在瘤学瘤学.
- 手术瘤学手术瘤学
- 胃肠病学 胃肠病学
背景情况:
- 局部胰腺腺癌带来了治疗挑战,特别是在对新辅助疗法不反应的患者中.
- 识别非响应者的特征和结果对于优化临床管理至关重要.
研究的目的:
- 确定局部胰腺腺癌患者的特征和结果,这些患者对新辅助疗法没有反应.
- 为指导临床实践关于非响应患者的管理.
主要方法:
- 对45名患有局部胰腺腺癌的患者进行了回顾性分析.
- 纳入标准:没有生化或放射反应,在第一次重新评估时没有远程进展.
- 进行化疗切换 (CS) 的患者与未接受化疗切换 (CS) 的患者之间的结局比较.
主要成果:
- 51.1%的患者进行了手术探索,大多数患者接受了切除.
- 切除患者的平均整体存活时间为48.6个月.
- 化学疗法转换 (CS) 队列显示了更高的进展率的趋势,但整体存活率与非CS组 (20.7 与 28.7 个月) 相似.
结论:
- 对一线新辅助疗法的不响应者具有较低的治疗意图切除率.
- 在可行的情况下,应考虑进行手术切除,即使在不响应患者中也是如此.
- 化疗切换 (CS) 是一种潜在的策略,用于初始新辅助疗法失败的患者.
相关概念视频
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
154
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
154
01:29Chronic Pancreatitis II: Collaborative Care
79
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
79
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
181
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
181
01:27Tumor Immunotherapy
493
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
493
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
238
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
238